Cantor Fitzgerald reiterated their buy rating on shares of Horizon Pharma (NASDAQ:HZNP) in a research report sent to investors on Wednesday, March 14th. They currently have a $17.00 target price on the biopharmaceutical company’s stock.
“Message in a bottle/vial. The four doctors we spoke with were positive on the safety and efficacy of Horizon’s Krystexxa. One of the four doctors believed that Krystexxa was a ‘wonder’ drug and was bullish on its growth prospects. The other three doctors were more measured. They all agreed that Krystexxa is a very good drug, but were not convinced it would be widely used among rheumatologists because it works best for a small group of refractory patients. The main barrier to uptake is not anaphylaxis. There are two reasons doctors don’t widely use Krystexxa: 1) the high cost relative to standard of care; 2) because it’s an IV, while the standard of care is oral.”,” the firm’s analyst wrote.
A number of other equities research analysts have also issued reports on the stock. ValuEngine lowered shares of Horizon Pharma from a buy rating to a hold rating in a report on Tuesday, March 13th. BidaskClub raised shares of Horizon Pharma from a sell rating to a hold rating in a report on Saturday, March 3rd. Morgan Stanley raised their target price on shares of Horizon Pharma from $14.00 to $16.00 and gave the company an equal weight rating in a report on Friday, March 2nd. Piper Jaffray reaffirmed a buy rating and issued a $22.00 target price on shares of Horizon Pharma in a report on Thursday, March 1st. Finally, Cowen reaffirmed a buy rating and issued a $24.00 target price on shares of Horizon Pharma in a report on Thursday, March 1st. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company’s stock. Horizon Pharma has an average rating of Buy and a consensus price target of $18.64.
Shares of HZNP traded down $0.54 during trading hours on Wednesday, hitting $13.65. The stock had a trading volume of 2,132,700 shares, compared to its average volume of 1,656,638. The company has a debt-to-equity ratio of 1.91, a current ratio of 1.63 and a quick ratio of 1.54. The stock has a market cap of $2,341.00, a P/E ratio of 11.57, a P/E/G ratio of 0.60 and a beta of 1.24. Horizon Pharma has a fifty-two week low of $9.45 and a fifty-two week high of $16.02.
Horizon Pharma (NASDAQ:HZNP) last issued its earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.29 EPS for the quarter, beating the Zacks’ consensus estimate of $0.22 by $0.07. The business had revenue of $274.22 million during the quarter, compared to analysts’ expectations of $264.48 million. Horizon Pharma had a negative net margin of 38.87% and a positive return on equity of 18.44%. The company’s quarterly revenue was down 11.6% compared to the same quarter last year. During the same period in the prior year, the business earned $0.64 earnings per share. equities analysts expect that Horizon Pharma will post 1.43 EPS for the current year.
Several institutional investors and hedge funds have recently made changes to their positions in HZNP. Ameriprise Financial Inc. grew its position in shares of Horizon Pharma by 419.1% during the third quarter. Ameriprise Financial Inc. now owns 2,127,694 shares of the biopharmaceutical company’s stock worth $26,979,000 after acquiring an additional 1,717,841 shares during the last quarter. Renaissance Technologies LLC grew its position in Horizon Pharma by 105.5% in the 4th quarter. Renaissance Technologies LLC now owns 2,279,400 shares of the biopharmaceutical company’s stock valued at $33,279,000 after buying an additional 1,170,000 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Horizon Pharma by 18.6% in the 3rd quarter. Dimensional Fund Advisors LP now owns 7,433,330 shares of the biopharmaceutical company’s stock valued at $94,254,000 after buying an additional 1,167,722 shares during the last quarter. William Blair Investment Management LLC grew its position in Horizon Pharma by 12.2% in the 4th quarter. William Blair Investment Management LLC now owns 8,826,079 shares of the biopharmaceutical company’s stock valued at $128,861,000 after buying an additional 958,414 shares during the last quarter. Finally, Two Sigma Investments LP purchased a new position in Horizon Pharma in the 4th quarter valued at $7,443,000. Institutional investors and hedge funds own 86.75% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Cantor Fitzgerald Reaffirms Buy Rating for Horizon Pharma (NASDAQ:HZNP)” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of U.S. & international copyright legislation. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/07/horizon-pharma-hznp-rating-reiterated-by-cantor-fitzgerald.html.
About Horizon Pharma
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.